• Deniz Çekiç, Emir ArmanMehmetMİnternal Medicine Department, Sakarya University, Sakarya, Turkey., Cihad GençAhmedAİnternal Medicine Department, Sakarya University, Sakarya, Turkey., Kubilay İşsever, İlhan Yıldırım, Bilal GençAhmedAİnternal Medicine Department, Sakarya University, Sakarya, Turkey., Hamad Dheir, and Selçuk Yaylacı.
• İnternal Medicine Department, Sakarya University, Sakarya, Turkey.
• Int. J. Clin. Pract. 2021 Dec 1; 75 (12): e14931.

ObjectiveNo effective treatment has yet been found for SARS-Cov-2, which caused a pandemic outbreak in 2019. It is crucial to detect the progression of COVID-19 in patients as early as possible. Fibrinogen to albumin ratio (FAR) has been used as a new inflammatory marker. We aimed to find out whether the use of the FAR as a predictor of mortality in COVID-19 patients provides clinical benefit.Materials And MethodsData from 590 patients with COVID-19 from March 15, 2020 to January 15, 2021 in medicine wards and intensive care units (ICU) were retrospectively analysed. Demographic data and other laboratory markers were collected from the electronic medical records. Relationship between FAR was investigated between patients in the survivor/non-survivor patients.FindingsThe mean FAR levels in patients who were non-survivor was 24.44 ± 30.3 (n = 272 and 11.29 ± 6.29 (n = 275) (P = .000) in patients survivor COVID-19 infection. In ROC curve for FAR, the threshold FAR that may pose a risk for mortality was determined as 13.84 ((AUC: 0.808 (0.771-0.844)); 74.9% sensitivity, 74.6% specificity; P = .000)).ResultAs a result of this study, increased FAR were found to be important markers in determining the mortality levels in COVID-19 patients.© 2021 John Wiley & Sons Ltd.

6 keywords...

hide…